The ratio of osteoprotegerin to fetuin-a ii independently associated with vascular stiffness in hemodialysis patients

Nephron - Clinical Practice

Volumn 123, Issue 3-4, 2013, Pages 165-172

  Kim, Hye Ryoun ^a   Kim, Su Hyun ^b   Han, Min Ji ^b   Yoon, Yu Sik ^c   Oh, Dong Jin ^d  

^a Departments of Laboratory Medicine   (South Korea)

^b Departments of Internal Medicine   (South Korea)

^c Chung Ang University   (South Korea)

^d Department of Surgery   (South Korea)

Author keywords

Calcification; Fetuin A; Heat shock protein 70; Hemodialysis; Osteoprotegerin; Vascular stiffness

Indexed keywords

FETUIN A; HEAT SHOCK PROTEIN 70; OSTEOPROTEGERIN; GLUCOSE; PHOSPHORUS;

ADULT; AGED; ANKLE BRACHIAL INDEX; ARTERIAL STIFFNESS; ARTERIAL WALL THICKNESS; ARTICLE; BLOOD VESSEL CALCIFICATION; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HEMODIALYSIS PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; CARDIO ANKLE VASCULAR INDEX; CARDIOVASCULAR PARAMETERS; CHRONIC GLOMERULONEPHRITIS; CORRELATION ANALYSIS; DIABETES MELLITUS; GLUCOSE BLOOD LEVEL; HEMODIALYSIS; HYPERTENSION; KIDNEY POLYCYSTIC DISEASE; RENOVASCULAR DISEASE;

AGED; ALPHA-2-HS-GLYCOPROTEIN; CAROTID INTIMA-MEDIA THICKNESS; FEMALE; HSP70 HEAT-SHOCK PROTEINS; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; OSTEOPROTEGERIN; RENAL DIALYSIS; VASCULAR STIFFNESS;

EID: 84880967711     PISSN: None     EISSN: 16602110     Source Type: Journal    
DOI: 10.1159/000353594     Document Type: Article

References (32)

1. London GM, Guerin AP, Marchais SJ, Metivier F, Pannier B, Adda H: Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 2003; 18: 1731-1740.
2. Kalantar-Zadeh K, Block G, Humphreys MH, Kopple JD: Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int 2003; 63: 1927-1939.
3. Savage T, Clarke AL, Giles M, Tomson CR, Raine AE: Calcified plaque is common in the carotid and femoral arteries of dialysis patients without clinical vascular disease. Nephrol Dial Transplant 1998; 13: 2004-2012.
4. London GM: Alterations of arterial function in end-stage renal disease. Nephron 2000; 84: 111-118.
5. Safar ME, London GM, Plante GE: Arterial stiffness and kidney function. Hypertension 2004; 43: 163-168.
6. Mourad JJ, Girerd X, Boutouyrie P, Laurent S, Safar M, London G: Increased stiffness of renal artery wall material in end-stage renal disease. Hypertension 1997; 30: 1425-1430.
7. Hermans MM, Brandenburg V, Ketteler M, Kooman JP, van der Sande FM, Gladziwa U, Rensma PL, Bartelet K, Konings CJ, Hoeks AP, Floege J, Leunissen KM: Study on the relationship of serum fetuin-A concentration with aortic stiffness in patients on dialysis. Nephrol Dial Transplant 2006; 21: 1293-1299.
8. Shroff RC, Shah V, Hiorns MP, Schoppet M, Hofbauer LC, Hawa G, Schurgers LJ, Singhal A, Merryweather I, Brogan P, Shanahan C, Deanfield J, Rees L: The circulating calcification inhibitors, fetuin-A and osteoprotegerin, but not matrix G1a protein, are associated with vascular stiffness and calcification in children on dialysis. Nephrol Dial Transplant 2008; 23: 3263-3271.
9. Jung JY, Hwang YH, Lee SW, Lee HJ, Kim DK, Kim SJ, Oh YG, Yang JS, Joo KW, Ahn CR, Oh KH: Factors associated with aortic stiffness and its change over time in peritoneal dialysis patients. Nephrol Dial Transplant 2010; 25: 4041-4048.
10. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Boyle WJ: Osteoprotegerin: a noble secreted protein involved in the regulation of bone density. Cell 1997; 89: 309-319.
11. Sigrist MK, Levin A, Er L, McIntyre CW: Elevated osteoprotegerin is associated with all-cause mortality in CKD stage 4 and 5 patients in addition to vascular calcification. Nephrol Dial Transplant 2009; 24: 3157-3162.
12. Talib A, Nakagawa N, Saito E, Matsuki M, Kobayashi M, Akasaka K, Hirayama T, Ishida H, Sato N, Hasebe N: The balance of fetuin-A and osteoprotegerin is independently associated with diastolic dysfunction in hemodialysis patients. Hypertens Res 2012; 35: 426-433.
13. Whitley D, Goldberg SP, Jordan WD: Heat shock proteins: a review of the molecular chaperones. J Vasc Surg 1999; 29: 748-751.
14. Krepuska M, Szeberin Z, Sotonyi P, Sarkadi H, Fehervari M, Apor A, Rimely E, Prohaszka Z, Acsady G: Serum levels of soluble Hsp70 is associated with vascular calcification. Cell Stress Chaperones 2011; 16: 257-265.
15. Pignoli P, Tremoli E, Poli A, Oreste P, Paoletti R: Intimal plus medial thickness of the arterial wall: a direct measurement with ultrasound imaging. Circulation 1986; 74: 1399-1406.
16. Persson J, Stavenow L, Wilstrand J, Israelsson B, Formgren J, Berglund G: Noninvasive quantification of atherosclerotic lesions. Reproducibility of ultrasonographic measurement of arterial wall thickness and plaque size. Arterioscler Thromb 1992; 12: 261-266.
17. Wolverson MK, Bashiti AM, Peterson GJ: Ultrasonic tissue characterization of atheromatous plaques using a high resolution real time scanner. Ultrasound Med Biol 1983; 9: 599-609.
18. Ix JH, Chertow GM, Shlipak MG, Brandenburg VM, Ketteler M, Whooley MA: Fetuin-A and kidney function in persons with coronary artery disease - data from the Heart and Soul Study. Nephrol Dial Transplant 2006; 21: 2144-2151.
19. Lebreton JP, Joisel F, Raoult JP, Lannuzel B, Rogez JP, Humbert G: Serum concentration of human alpha 2 HS glycoprotein during the inflammatory process: evidence that alpha 2 HS glycoprotein is a negative acute-phase reactant.J Clin Invest 1979; 64: 1118-1129.
20. Price PA, Lim JE: The inhibition of calcium phosphate precipitation by fetuin is accompanied by the formation of a fetuin-mineral complex. J Biol Chem 2003; 278: 22144-22152.
21. Ford ML, Tomlinson LA, Smith ER, Rajkumar C, Holt SG: Fetuin-A is an independent determinant of change of aortic stiffness over 1 year in non-diabetic patients with CKD stages 3 and 4. Nephrol Dial Transplant 2010; 25: 1853-1858.
22. Kiechl S, Schett G, Wenning G, Redlich K, Oberhollenzer M, Mayr A, Santer P, Smolen J, Poewe W, Willeit J: Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation 2004; 109: 2175-2180.
23. Abedin M, Omland T, Ueland T, Khera A, Aukrust P, Murphy SA, Jain T, Gruntmanis U, McGuire DK, de Lemos JA: Relation of osteoprotegerin to coronary calcium and aortic plaque (from the Dallas Heart Study). Am J Cardiol 2007; 99: 513-518.
24. Othmane TH, Bakonyi G, Egresits J, Fekete BC, Fodor E, Jarai Z, Jekkel C, Nemcsik J, Szabo A, Szabo T, Kiss I, Tisler A: Effect of sevelamer on aortic pulse wave velocity in patients on hemodialysis: a prospective observational study. Hemodial Int 2007; 11(suppl 3):S13-S21.
25. Kim SM, Lee J, Ryu OH, Lee KW, Kim HY, Seo JA, Kim SG, Kim NH, Baik SH, Choi DS, Choi KM: Serum osteoprotegerin levels are associated with inflammation and pulse wave velocity. Clin Endocrinol (Oxf) 2005; 63: 594-598.
26. Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, Scully S, Tan HL, Xu W, Lacey DL, Boyle WJ, Simonet WS: Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998; 12: 1260-1268.
27. Martin-Ventura JL, Leclercq A, Blanco-Colio LM, Egido J, Rossignol P, Meilhac O, Michel JB: Low plasma levels of Hsp70 in patients with carotid atherosclerosis are associated with increased levels of proteolytic markers of neutrophil activation. Atherosclerosis 2007; 194: 334-341.
28. Wright BH, Corton JM, El-Nahas AM, Wood RF, Pockley AG: Elevated levels of circulating heat shock protein (Hsp70) in peripheral and renal vascular disease. Heart Vessels 2000; 15: 18-22.
29. Pockley AG, Georgiades A, Thulin T, de Faire U, Frostegard J: Serum heat shock protein 70 levels predict the development of atherosclerosis in subjects with established hypertension. Hypertension 2003; 42; 235- 238.
30. Yao Y, Watson AD, Ji S, Bostrom KI: Heat shock protein 70 enhances vascular bone morphogenic protein-4 signaling by binding matrix G1a protein. Circ Res 2009; 105: 575-584.
31. Lebherz-Eichinger D, Ankersmit HJ, Hacker S, Hetz H, Kimberger O, Schmidt EM, Reiter T, Horl W, Haas M, Krenn CG, Roth GA: HSP27 and HSP70 serum and urine levels in patients suffering from chronic kidney disease.Clin Chim Acta 2012; 413: 282-286.
32. Prohaszka Z, Singh M, Nagy K, Kiss E, Lakos G, Duba J, Fust G: Heat shock protein 70 is a potent activator of the human complement system. Cell Stress Chaperones 2002; 7: 17-22.